We examined the integrin expression 
Metastasis is the major cause of mortality in patients with malignant tumours. It consists of a series of events, of which the most important are the detachment of cancer cells, their migration to and then transportation by the drculation, adhesion to vascular endothelial cells, migration through the vascular wall and, finally, proliferation in the parenchyma of the target organs (Nicolson, 1988) . The interaction of tumour cells with vascular endothelial cells is thought to be one of the most important steps in haematogenous metastasis (Albelda & Buck, 1990; Chammas & Brentani, 1991) .
A dramatic step forward in the analysis of this interaction was taken with the identification of integrins, a family of adhesion molecules. The integrins are transmembrane glycoproteins that form heterodimers consisting of non-covalently associated a-and a-subunits (Hynes, 1987;  Hemler, 1990) .
The majority of integrins can be grouped into several subfamilies defined by the presence of a common A-subunit.
Many receptors for ECM proteins including the integrin family have been found on tumours (Ruoslahti & Pierschbacher, 1987) . In the first step of their interaction with endothelial cells, melanoma (Martin-Padura et al., 1991) and fibrosarcoma cells (Kawaguchi et al., 1992) adhere to endothelial cells through VLA-4/VCAM-1 interaction. There have been several studies on integrin expression of lung cancers (Damjanovich et al., 1992; Mette et al., 1993; Suzuki et al., 1993 ) and the ability of lung cancer cells to adhere to ECM proteins (Mette et al., 1993 
Material and inERMo7
Lung cancer cell lines Nimeteen lung cancer cell lines were used in this study. LC18, LC27, LC81, LC127, LC133, LC142, LC146, LC148 and LC155 were established in our laboratory (Inoue et al., 1990; Shijubo et a., 1991) and A549, EBC-1, LClsq, RERF-LC-MA, SBC-1, SBC-2, SBC-3, SBC-5, Lu134-A-H and LC65C (Lieber et el., 1976; Terasaki et al., 1986; Imanisi et al., 1989; Harada et al., 1990) were supplied by the Japan Cancer Research Resources Bank. LC18, LC81, LC127, LC133, LC142, LC146, LC155 and A549 were establshed from lung adenocarcinoma, EBC-1 and LCI-sq from lung squamous cell carcinoma, LC148, Lu134-A-H, RERF-LC-MA, SBC-1, SBC-2, SBC-3 and SBC-5 from small-cell lung carcinoma and LC27 and LC65C from large cell lung carcinoma. These cell lines were adherent and maintaind in RPMI-1640 medium suplemented with 2 x 10-3 M L-glutamie, 10% fetal calf serum (FCS), 100 U ml-' penicilln and 100 ag ml-' streptomycin (hereafter referred to as the 'complete medium'). For binding assays, tumour cells were treated with PBS, pH 7.4, containing 0.05% trypsin (Sigma, St Louis, MO, USA) and 0.02% EDTA, collected, washed three times with PBS and resuspended in complete medium. The viability of tumour cells was more than 95% as judged from the ability to exclude trypan blue.
Reagents
Human fibronection, laminin and collagen type I were purchased from Chemicon (Temecula, CA, USA). The ECM proteins were dissolved in Ca2+, Mg2+-free PBS. RGDcontaining peptide (GRGDSP) and III CS CS-1 peptide (CDELPQLVTLPNLHGPEILDVPST) were purchased from Iwakiglass Institute, (Tokyo, Japan). RGD peptide is the recognition site of VLA-3 and VLA-5, and Ill CS CS-1 peptide is the recognition site of VLA-4 (Hynes, 1992 (Table I ). The fraction of positive cells after background subtraction was recorded for each sample study. (Koizumi et al., 1988) for 1 h. Following preincubation with the MAbs, 12,000 tumour cells were added directly to the chambers without washing. The binding assays were carried out as described above. Incubation time of the assays was I h. Another senres of inhibition assays was performed to assess the effect of the synthetic fragments of fibronectin. The tumour cells were preincubated with 100 jg nm1' RGD or 100 ;Lg ml-' CS-l peptide at 3T7C in 5% carbon dioxide for 1 h. Following preincubation with the synthetic fragments, the tumour cells were added directly to the chambers without washing. Assays were carried out as described above, except that the incubation time was 30 min.
Binding inhibition of lung cancer cells tofibronectin using RGD or CS-I peptide Binding inhibition assays to fibronectin with RGD or CS-1 peptide were performed using the 17 lung cancer lines that had adhered strongly to fibronectin (Figure 3) . RGD peptide inhibited the binding of tumour cells to fibronection ( Figure  3) . RGD Figure 4 . Figure 4a depicts a case of low binding (by SBC-1) to the HUVECs' surface, and Figure 4b shows strong binding (by LC27). Figure 4c (Dransfield & Hogg, 1989 ) and divalent cations (Statz et al., 1989) , we Inhibition assays to HUVECs with the MAbs (4B4 or SG/19) to the PI subunit were performed (Figure 7 ). Both MAbs showed great inhibition of adhesion ranging from 51% to 83% inhibition, in comparison with the binding with an isotype-matched negative control MAb. Next, assays were performed using RGD or CS-1 peptide; assays to these failed to inhibit binding of tumour cells to HUVECs in all examined ines (data not shown).
Integrins mediate ECM-cell or cell-cell interactions (Hemker, 1990a (Hynes, 1987) and the metastasis of malignant tumours (Chammas & Brentani, 1991) . Metastatic subtypes of Lewis lung carcinoma expessed a P4 more frequently than did non-metastatic subtypes (Perrotti et al., 1990) . Rhabdomyosarcoma cells transfected with genes from VLA-2 became substantially more nmtastatic than the orginal tumour cells (B.M.C. . Both antibodis to integrins and synthetc pepides of ECM proteins prevented the formation of the lung nodules in mice injected with B16 melanoma cells (Humphries et al., 1986) .
There is ncreasig evidence that neoplasti transformation is associated with modification of integrin expression (Dedhar & Saulnier, 1990) . Human lung cancers expressed at least 20 times more £2 subunit RNA mesage than normal adult human lung tissue (FA. Chen et al., 1991) . Modification of integrin expression may affect the ability to meastasase.
Integrin expression in tumours such as mnoma (Kramer et al., 1991) , neuroblastoma (Favrot et al., 1991) and osteosarcoma (Lauri et al., 1991) has been extensively studied. Several studies have also focused on lung cancers (Damianovich et al., 1992Z Mette et al., 1993 Suzuki et al., 1993 ), but have not clarly shown distinct patterns of integrin expresson among various histological types of lung cancer.
Most lung cancer cell lines as well as normal bronchial epithlial cells (Strooper et al., 1989) appear to express the A subunit (Feklman et at., 1991) . Although several investigators (Ruff & Pert, 1984; Bunn et al., 1985; Ball et at., 1986) have reported the am subunit in a small number of small cell lung cancer lines, very little expression of the P2 subunit was found on small cell lung cancer cells (Feldman et al., 1991) . Our data from six small cell lung cancer lines were in ageement with the result of Feldman et al., but all lung cancer cell lines we eamined, r dss of histological type, showed zero expresson of the P2 subunit on their surfaces. Costantini et al. (1990) reported that exprson of the P4 subunit occurs in non-small cell lung cancers, but not in small cell lung ancers. In our study, P 4 was expressd in 7 of 12 non small cell lung cancer lines and in two of seven small-cel lung cancer lines.
This study showed that the a-subunits most consistently (Hynes, 1992 (Ruoslahti, 1988 The ICAM-l/LFA-1 (Makgoba et al., 1988) , VCAM-1/ VLA-4 (Martin-Padura et al., 1991) and ELAM-I/sialyl-Le pathways (Walz et al., 1990) 
